These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 18280056)

  • 21. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1053-8. PubMed ID: 17398023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
    Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.
    Deger S; Boehmer D; Roigas J; Schink T; Wernecke KD; Wiegel T; Hinkelbein W; Budach V; Loening SA
    Eur Urol; 2005 Apr; 47(4):441-8. PubMed ID: 15774239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?
    Khuntia D; Reddy CA; Mahadevan A; Klein EA; Kupelian PA
    Cancer; 2004 Mar; 100(6):1283-92. PubMed ID: 15022298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose escalation for prostate cancer using the three-dimensional conformal dynamic arc technique: analysis of 542 consecutive patients.
    Jereczek-Fossa BA; Vavassori A; Fodor C; Santoro L; Zerini D; Cattani F; Garibaldi C; Cambria R; Fodor A; Boboc GI; Vitolo V; Ivaldi GB; Musi G; de Cobelli O; Orecchia R
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):784-94. PubMed ID: 18191332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of postradiotherapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer.
    Zelefsky MJ; Ben-Porat L; Chan HM; Fearn PA; Venkatraman ES
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):382-8. PubMed ID: 16965990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
    Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D; Tyldesley S; Pickles T;
    Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
    Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
    Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment outcomes of three-dimensional conformal radiotherapy for localized prostate carcinoma: a large community-based experience.
    McCloskey SA; Ellerbroek NA; McCarthy L; Malcolm AW; Tao ML; Wollman RC; Rose CM
    Cancer; 2004 Dec; 101(11):2693-700. PubMed ID: 15494974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of modest dose irradiation in combination with long-term endocrinal treatment for high-risk prostate cancer: a preliminary report.
    Sasaki T; Nakamura K; Shioyama Y; Ohga S; Urashima Y; Terashima H; Koga H; Naito S; Noma H; Komatsu K; Yamaguchi A; Honda H
    Jpn J Clin Oncol; 2004 Jul; 34(7):420-4. PubMed ID: 15342670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is there a role for short-term hormone use in the treatment of nonmetastatic prostate cancer?
    Horwitz EM; Hanlon AL; Pinover WH; Hanks GE
    Radiat Oncol Investig; 1999; 7(4):249-59. PubMed ID: 10492166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.
    Liauw SL; Fricano J; Correa D; Weichselbaum RR; Jani AB
    Cancer; 2009 Apr; 115(8):1784-90. PubMed ID: 19208426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer.
    Peters CA; Stock RG; Blacksburg SR; Stone NN
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):24-9. PubMed ID: 18692325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and biochemical outcome of conventional dose radiotherapy for localized prostate cancer.
    Catton C; Gospodarowicz M; Mui J; Panzarella T; Milosevic M; McLean M; Catton P; Warde P
    Can J Urol; 2002 Feb; 9(1):1444-52; discussion 1453. PubMed ID: 11886597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?
    Galalae RM; Martinez A; Nuernberg N; Edmundson G; Gustafson G; Gonzalez J; Kimming B
    Strahlenther Onkol; 2006 Mar; 182(3):135-41. PubMed ID: 16520907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer.
    Zelefsky MJ; Kattan MW; Fearn P; Fearon BL; Stasi JP; Shippy AM; Scardino PT
    Urology; 2007 Aug; 70(2):283-7. PubMed ID: 17826490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer.
    Kotecha R; Yamada Y; Pei X; Kollmeier MA; Cox B; Cohen GN; Zaider M; Zelefsky MJ
    Brachytherapy; 2013; 12(1):44-9. PubMed ID: 22831750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
    Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer.
    Zelefsky MJ; Moughan J; Owen J; Zietman AL; Roach M; Hanks GE
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1053-61. PubMed ID: 15234039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.